Organigram Global (OGI) to Release Earnings on Tuesday

Organigram Global (NASDAQ:OGI) is expected to release its Q4 2025 results before the market opens on Tuesday, December 16th. Analysts expect Organigram Global to post earnings of ($0.01) per share and revenue of $73.0180 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, December 16, 2025 at 8:00 AM ET.

Organigram Global Stock Up 17.1%

OGI stock opened at $1.92 on Friday. The company has a market cap of $259.22 million, a PE ratio of 38.41 and a beta of 1.50. Organigram Global has a twelve month low of $0.85 and a twelve month high of $2.08. The business’s 50-day simple moving average is $1.68 and its 200 day simple moving average is $1.58.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on OGI shares. Weiss Ratings reissued a “sell (d)” rating on shares of Organigram Global in a report on Wednesday, October 8th. Wall Street Zen raised shares of Organigram Global from a “sell” rating to a “hold” rating in a report on Saturday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On Organigram Global

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its stake in shares of Organigram Global by 1,678.1% in the 3rd quarter. Bank of America Corp DE now owns 37,357 shares of the company’s stock valued at $76,000 after purchasing an additional 35,256 shares during the period. Two Sigma Investments LP bought a new position in Organigram Global during the third quarter worth about $907,000. Finally, Tidal Investments LLC grew its holdings in Organigram Global by 4.9% during the 2nd quarter. Tidal Investments LLC now owns 2,646,879 shares of the company’s stock valued at $3,573,000 after buying an additional 124,356 shares in the last quarter. 34.63% of the stock is owned by institutional investors.

About Organigram Global

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.